07:00 , May 29, 2006 |  BC Week In Review  |  Company News

bioMerieux, Proteome Sciences, Trinity deal

BIM received a license to use PRM’s biomarkers to diagnose stroke. The biomarkers were discovered using PRM’s ProteoSHOP technology. Further terms were not disclosed. Separately, BIM will sell its coagulation diagnostics business to TRIB for...
01:05 , May 26, 2006 |  BC Extra  |  Company News

Trinity to buy bioMerieux's coagulation business

bioMerieux (Euronext:BIM) will sell its coagulation diagnostics business to TRIB for $40 million at closing plus two payments totaling up to $11.9 million over the following 24 months. BIM said the deal will let it...
08:00 , Feb 4, 2002 |  BC Week In Review  |  Company News

Trinity, Xtrana deal

TRIB completed its acquisition of Biopool, the hemostasis division of XTRN (see BioCentury, Nov. 19, 2001). As a result, TRIB said it will incur a one-time charge of $2.9 million for the year ended Dec....
07:00 , Jun 25, 2001 |  BC Week In Review  |  Company News

Biopool International Inc./Xtrana management update

Biopool International Inc./Xtrana (BIPL), Ventura Calif.   Business: Diagnostics/Imaging   Hired: Melanie Harder as VP of sales and marketing, formerly director of marketing and sales at MedLogic Global Corp.   Promoted: Timothy Dahltrop to CEO...
07:00 , Jun 21, 2001 |  BC Extra  |  Company News

Biopool/Xtrana names CEO

Diagnostics play BIPL promoted Timothy Dahltorp as CEO and a director. He will remain CFO....
07:00 , Apr 16, 2001 |  BC Week In Review  |  Company News

Agen Biomedical Ltd., Biopool International Inc./Xtrana diagnostics/imaging news

The companies settled a suit filed by Agen last year in the U.S. District Court for the Northern District of California that claimed BIPL's D-dimer test kits infringe Agen's U.S. Patent No. 4,758,524 covering tests...
08:00 , Feb 12, 2001 |  BC Week In Review  |  Clinical News

MiniQuant D-dimer Assay System regulatory update

The FDA granted 510(k) marketing clearance for BIPL's MiniQuant, a quantitative method for determining D-dimer containing fragments in plasma. Increased levels of D-dimer are seen in cardiovascular conditions, including deep vein thrombosis, pulmonary embolism and...
08:00 , Feb 12, 2001 |  BC Week In Review  |  Company News

Biopool management update

Biopool International Inc. (BIPL), Ventura Calif.   Business: Diagnostics/Imaging   Resigned: John Wheeler as CEO   Transition: Timothy Dahltorp, CFO, as interim COO  ...
08:00 , Feb 9, 2001 |  BC Extra  |  Company News

Biopool CEO resigns

John Wheeler resigned as CEO of BIPL. CFO Timothy Dahltorp was appointed interim COO, and the board has created an executive management committee. The company said Wheeler's resignation resulted from differences with the board following...
08:00 , Feb 8, 2001 |  BC Extra  |  Company News

Biopool gets clearance for D-dimer assay

The FDA granted 510(k) marketing clearance for BIPL's MiniQuant D-dimer Assay System, a quantitative method for determining D-dimer containing fragments in plasma. Increased levels of D-dimer are seen in cardiovascular conditions, including deep vein thrombosis,...